A Study to Assess Safety, Tolerability and Efficacy of Garetosmab Versus Placebo Administered Intravenously (IV) in Adult Participants With Fibrodysplasia Ossificans Progressiva (FOP)

NCT05394116 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

63

Enrollment

INDUSTRY

Sponsor class

Conditions

Fibrodysplasia Ossificans Progressiva

Interventions

DRUG: Garetosmab
DRUG: Placebo

Sponsor

Regeneron Pharmaceuticals